AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)
GUILFORD, Conn., April 25, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., an AI driven clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, today announced the acquisition of EntreChem, S.L.’s…